Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind Study of FOND (Fosaprepitant, ONdansetron, Dexamethasone) Plus Either Olanzapine 2.5 mg Versus 5 mg for the Prevention of Chemotherapy Induced Nausea and Vomiting in Patients Receiving High-dose Melphalan Conditioning: The FONDO-LOW Study

NCT06588413 is registered in ClinicalTrials.gov with Augusta University as lead sponsor.

NCT NCT06588413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06588413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind Study of FOND (Fosaprepitant, ONdansetron, Dexamethasone) Plus Either Olanzapine 2.5 mg Versus 5 mg for the Prevention of Chemotherapy Induced Nausea and Vomiting in Patients Receiving High-dose Melphalan Conditioning: The FONDO-LOW Study
Lead sponsor
Augusta University
Phase
Phase 3
Overall status
Recruiting
Start date
September 17, 2024
Completion date
October 31, 2027
Enrollment
172 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autologous stem cell transplantation, multiple myeloma